Tanvex BioPharma Inc
TWSE:6541
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KY |
|
Tanvex BioPharma Inc
TWSE:6541
|
10.9B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
66.6B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
36.4B EUR |
Loading...
|
Market Distribution
| Min | -329.6% |
| 30th Percentile | 12% |
| Median | 29.8% |
| 70th Percentile | 56.6% |
| Max | 403.2% |
Other Profitability Ratios
Tanvex BioPharma Inc
Glance View
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Tanvex BioPharma Inc is -87%, which is below its 3-year median of 31.4%.
Over the last 3 years, Tanvex BioPharma Inc’s Gross Margin has decreased from -68.3% to -87%. During this period, it reached a low of -87% on Sep 30, 2025 and a high of 97.2% on Dec 31, 2023.
